

## **Supporting Information for**

## Extrachromosomal Telomere DNA Derived from Excessive Strand Displacements

Junyeop Lee, Jina Lee, Eric J. Sohn, Angelo Taglialatela, Roderick J. O'Sullivan, Alberto Ciccia, and Jaewon Min

Correspondence to: Jaewon Min Email: <u>JM5092@cumc.columbia.edu</u>

#### This PDF file includes:

Figures S1 to S6 Extended Methods Extended Discussion SI References Uncropped gel



G-rich probe

- -



# Figure S1



Whole - 140ng Chromatin&Nucleoplasm&Cytoplasm - 70ng

Figure S1, related to Figure 1. 4SET assay, a simple and efficient method for detecting singlestranded extrachromosomal telomeric DNA. (A) Comparison of genomic DNA purification between DNeasy Blood & Tissue Kit (Qiagen, 69504) and our 4SET method in U2OS and SaoS2 cells. (B) Comparison between Dig-labeled strand-specific probes and standard end-labeling probes. (C) Comparison of 4SET results with DNA dissolved at 4°C overnight vs 55°C for 2 hours, followed by 4°C overnight. Observed smear signals potentially indicate the presence of nicked or gapped DNA. The arrow marked in the gel well is likely indicative of a DNA intermediate structure. This may be a result of annealing coupled with spontaneous branch migration, processes that are potentially facilitated by the high temperature conditions. The graph to the right displays the quantified signals potentially indicative of nicked or gapped DNA (mean ± SD; unpaired t-test). (D) Western blot analysis of the whole, chromatin (Chr.), and soluble using anti-Histone H3, Lamin A/C, Emerin, GAPDH, and beta-actin for the validation of cell fractions. (E) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 1C. (F) 4SET assay for soluble fractions of U2OS and SaoS2 cells to determine the minimum sample requirement. (G) Western blot analysis of the whole, chromatin (Chr.), and soluble fractions using PML antibody. (H) Western blot analysis of Saos2 Wild-type (WT) and PML Knock-out cells using PML antibody, along with a Ponceau image as a loading control. (I) 4SET assay for SaoS2 WT and PML Knock-out cells after fractionation into Whole and soluble fractions. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA staining of gel image (loading control). (J) C-circle assay using DNA in (I) (top). Quantification of C-circle assay (mean ± SD; unpaired t-test) (bottom). (K) 4SET assay conducted using a nucleotide ladder (RiboRuler) to measure the size of C-rich single-stranded DNA in SaoS2 soluble fraction, analyzed on both 0.5% and 1% agarose gels. (L) 4SET assay for SaoS2 treated with Zeocin (100 µg/ml), Etoposide (ETO) (10 µM), or Camptothecin (CPT) (0.25 µM) for 24 hrs. (M) Quantification of the C-circle assay in Fig. 1E (SaoS2 cells). Relative amount of C-circle assay products (mean ± SD; unpaired t-test). (N) Cell fractionation using E1 and E2 buffers to separate chromatin, nucleoplasm, and cytoplasm. (O) Western blot analysis conducted using the fractionated DNAs in (N) using anti-Histone H3, Lamin A/C, GAPDH, and PML for the validation of cell fractions. (P) 4SET assay for fractionated DNAs in (N).



TelG (G-rich) probe

## Figure S2, related to Figure 2. The presence of C-rich telomeric single-stranded DNA. (A) S1

nuclease assay on U2OS and SaoS2 soluble DNA fractions. **(B)** Lambda exonuclease assay on U2OS soluble DNA fraction. **(C)** Telomere-FISH with TelG (G-rich) and TelC (C-rich) PNA probes for chromatin (denatured FISH) and soluble fractions (native FISH).





Figure S3, related to Figure 3. MRE11 nuclease activity suppresses the generation of C-rich ssDNA. (A) SYBR DNA image (loading control) for G-rich probe and C-rich probe gels in Fig. 3D. (B) 4SET assay for HeLa LT cells with or without Mirin treatment. Samples were fractionated into soluble DNA fraction or whole DNA. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. SYBR DNA image (loading control) for G-probe gel. (C) 4SET assay for soluble DNA fractions of HeLa LT and U2OS cells. (D) 4SET assay for SaoS2 cells with Mirin, PFM01, PFM39 or mock (control) treatments. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA image (loading control) for G-rich probe and Crich probe gels. (E) Western blot of SaoS2 post-transfection with siLuciferase (siLuc) or siMRE11. (F) 4SET for SaoS2, with and without Mre11 treatment post siLuc or siMRE11s transfection. (G) Quantification of 4SET from F, presenting the quantification of relative amount of C-rich ssDNAs (mean ± SD; unpaired t-test). (H) Western blot of U2OS cells expressing MRE11 WT or H129N. (I) 4SET assay for MRE11 WT or H129N expressing U2OS cells treated with CPT (0.25 μM) for 48 hrs (J) Quantification of 4SET from I. representing the quantification of relative amount of C-rich ssDNAs (mean ± SD: unpaired t-test). (K) 4SET for SaoS2 WT and SaoS2 PML KO with/without Mirin treatment. (L) Quantification of 4SET from K, showing relative C-rich ssDNA (whole) levels (mean ± SD). (M) Native IdU pulldown was conducted using IdU (3D4) antibody for Saos2 WT and Saos2 PML KO after IdU incorporation. IgG served as a negative control. Chromatin DNA was also included to control for DNA quantity. (N) Quantification of the native IdU-pulldown assay in M; Relative amount of nascent C-rich ssDNAs (mean ± SD; unpaired t-test).

Figure S4



5' flap in lagging daughter strand (C-rich)





SYBR DNA



SYBR DNA

## Figure S4



Figure S4, related to Figure 4. C-rich ssDNAs are derived from lagging strand during the Okazaki fragment processing. (A) Relative amount of DNA2 mRNA levels measured by quantitative-PCR (left) and DNA2 Western blot (right) of U2OS cells transfected with siRNAs targeting DNA2 or control (siLuc). (B) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 4C. (C) Relative amount of FEN1 mRNA levels measured by quantitative-PCR (left) and FEN1 Western blot (right) of U2OS cells transfected with siRNAs targeting FEN1 or control (siLuc). (D) Illustration depicting 5' flap processing at lagging strand telomeres by DNA2-RPA or FEN1-PCNA. (E) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 4E. (F) 4SET assay for U2OS cells with PARPi (Talazoparib), Mirin, or mock (control) treatments. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA images (loading control) for G-rich probe and C-rich probe gels. (G) Western blot of SaoS2 post-transfection with siLuc or siPRIMPOL. (H) 4SET assay for SaoS2 cells after transfection of siRNAs targeting PRIMPOL, or control (siLuc) with or without Mirin treatment. G-rich probe was used to detect C-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA image (loading control) for G-rich probe. (I) Western blot of U2OS WT and U2OS PRIMPOL KO cells post-transfection with mCherry-PRIMPOLs (WT or S255D) or control vector. (J) 4SET assay for U2OS PRIMPOL KO cells after transfection of PRIMPOL WT, S255D, or control cDNA plasmid with or without Mirin treatment. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA images (loading control) for G-rich probe and C-rich probe gels.

Figure S5



Figure S5





Figure S5, related to Figure 5. ATRX suppresses the generation of C-rich ssDNAs. (A) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 5D. (B) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 5G. (C) Relative amount of FANCM mRNA levels measured by quantitative-PCR in U2OS cells transfected with siRNAs targeting FANCM or control (siLuc). (D) Relative quantification of R-loops at telomeres using the 7p TERRA primer following DNA/RNA hybrid immunoprecipitation with the S9.6 antibody or IgG in U2OS cells transfected with siRNAs targeting FANCM or control (siLuc). (E) 4SET assay for U2OS cells after transfection of siRNAs targeting FANCM or control (siLuc) with Mirin treatment. G-rich probe was used to detect Crich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA image (loading control) for G-rich probe gel. (F) Western blot analysis of U2OS RAD51AP1 KO (C1) or control. (G) 4SET assay for U2OS RAD51AP1 KO (C1) or control with Mirin treatment. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA image (loading control) for G-rich probe gel. (H) 4SET assay for U2OS treated with Pyridostatin (PDS; 0, 5, 10 μM, 48 hrs). (I) Quantification of 4SET from H. representing the quantification of relative amount of C-rich ssDNAs (mean ± SD; unpaired t-test). (J) 4SET assay for HeLa LT TERC KO or HeLa LT TERC KO cells expressing shRNA targeting ATRX gene (ATRX 590) with or without Mirin or PARPi treatment. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. SYBR DNA image (loading control) for G-rich probe gel.





Figure S6, related to Figure 6. CST complex-mediated priming and subsequent strand displacements by DNA polymerase delta generates C-rich ssDNAs. (A) Relative amount of STN1 mRNA levels measured by quantitative-PCR (top) and STN1 Western blot (bottom) in U2OS and SaoS2 cells expressing shRNA targeting STN1 gene or control (shNT). (B) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 6D. (C) 4SET assay for U2OS cells expressing shRNAs targeting STN1, or non-targeting (NT) control. Cells were treated with Mirin (50 µM, 48 hr). SYBR DNA images (loading control) for G-rich probe and C-rich probe gels. (D) Western blot of U2OS cells expressing shRNA targeting POLD3 gene or control (shNT). (E) SYBR DNA images (loading control) for G-rich probe and C-rich probe gels in Fig. 6F. (F) 4SET assay for Mirin treated U2OS cells along with aphidicolin, CD437 or control. Samples were fractionated into soluble DNA fraction or whole DNA. G-rich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect Grich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA image (loading control) for G-rich probe gel. (G) 4SET assay for Mirin treated U2OS WT or BLM KO cells. Grich probe was used to detect C-rich telomeric sequences, and C-rich probe was used to detect G-rich telomeric sequences. C-rich single stranded DNAs are indicated by an arrow. SYBR DNA image (loading control) for G-rich probe gel. (H) Quantification of the 4SET assay in G; as the relative amount of C-rich ssDNA (whole). (mean ± SD; unpaired t-test). (I) SYBR DNA images (loading control) for Grich probe and C-rich probe gels in Fig. 6G.

### **Extended Methods**

### Cell culture

U2OS, SaoS2, and HeLa LT cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, Penicillin-Streptomycin (Gibco, 15070063). To prevent mycoplasma contaminations, we regularly used Plasmocin Prophylactic (InvivoGen) to maintain the cells according to the manufacturer's protocol.

Cells were subjected to the following treatments with specific concentrations and durations: Mirin (50  $\mu$ M, 48 hr), Talazoparib (5  $\mu$ M, 48 hr), Aphidicolin (0.2  $\mu$ M, 48 hr), CD437 (0.2  $\mu$ M, 48 hr), Pyridostatin (5 or 10  $\mu$ M, 48 hr), Camptothecin (0.25  $\mu$ M, 24 hr), Etoposide (10  $\mu$ M, 48 hr), Zeocin (100  $\mu$ g/ml, 48 hr), and doxycycline treatment (1  $\mu$ g/ml, 24 or 48 hr for U2OS expressing pCW MRE11 WT or H129N, 1 week for U2OS<sup>ATRX</sup>). Negative control (mock) samples were untreated.

### siRNA-mediated knockdown

siRNA oligos were purchased from Sigma-Aldrich (10 nmol) and purified by desalting. The dTdT overhangs were added to ensure the stability of siRNA. The siRNAs were transfected into the cells at a final concentration of 20 nM, along with 2  $\mu$ l of Lipofectamine 3000 (Thermo scientific, L3000001) according to the manufacturer's protocol.

The following siRNAs were used: siLuc: UCGAAGUAUUCCGCGUACGUU, siDNA2#1: CAGUAUCUCCUCUAGCUAGUU (1), siDNA2#2: AUAGCCAGUAGUAUUCGAUUU (1), siFEN1#1: UGACAUCAAGAGCUACUUU (2), siFEN#2 : CCAUUCGCAUGAUGGAGAA (2), siPRIMPOL: GAGGAAACCGUUGUCCUCAGUG (3), siFANCM: AAGCUCAUAAAGCUCUCGGAA (4), siMRE11: ACAGGAGAAGAGAUCAACU (5),

### Lentiviral shRNA knockdown and sgRNA knockout.

Lentiviruses were generated by transfecting shRNA vectors targeting human POLD3 (6), STN1 (7), ATRX(8), or the control vector, or sgRNA vectors targeting human PML exon 3 (sense: CACCGGcggtaccagcgcgactacg, antisense: AAACcgtagtcgcgctggtaccgCC) inserted in pLentiV2 vector (Addgene, 52961) along with pMD2.G and psPAX into 293T cells. Transfection was carried out using TransIT (Mirus) following the manufacturer's protocol. After 24 hours, the medium was replaced with fresh medium, and cells were incubated for an additional 24 hours. Supernatants containing the lentiviruses were collected and passed through a 0.45  $\mu$ m syringe filter. The collected supernatants were then concentrated using 4x virus concentrator solution. This solution consisted of phosphate-buffered saline (PBS) at pH 7.2 containing 1.2 M sodium chloride (NaCI) and 40% (v/w) PEG-8000. The concentrated virus pellets were used to infect target cells, and 0.5  $\mu$ g/ml polybrene was added to enhance viral transduction. Cells were selected under either 5  $\mu$ g/ml Blasticidin-S (Invivogen) for two weeks or 5  $\mu$ g/ml Puromycin (Invivogen) for 5 days to establish stable cell lines expressing the desired shRNA or sgRNA. After selection, cells are cloned and confirmed by RT-qPCR or Western blot. Proper biosafety procedures were followed when working with lentiviruses.

#### Plasmid

cDNAs for MRE11 WT and H129N were obtained from Addgene (#177168, #177169) and inserted into pCW vector. The pCW-MRE11 WT or H129N vectors were employed to produce lentivirus for a

doxycycline-inducible expression system of either MRE11 WT or H129N, following above mentioned-protocol.

cDNA encoding PRIMPOL was synthesized from Integrated DNA Technologies (IDT) and cloned into pCS2(+) NLS-mCherry vector. PRIMPOL S255D mutant was generated using Q5 site-directed mutagenesis kit (NEB). The pCS2 NLS-mCherry-PRIMPOL WT or S255D vectors were used for transfection in U2OS PRIMPOL KO cells using TransIT (Mirus) according to the manufacturer's protocol. cDNA expression and transfection efficiency were assessed by mCherry signal and western blot.

#### Strand-Specific Southern for Single-stranded Extrachromosomal Telomeres (4SET) - DNA preparation procedure

Cells were harvested using Trypsin-EDTA and then divided into separate tubes for fractionation. The cells were pelleted via centrifugation (500 g, 5 min) and washed with PBS. Cell pellets can be preserved at -80°C prior to 4SET analysis. For the whole DNA fraction, cells were lysed by adding lysis buffer (0.1 M Tris pH 8.0, 0.1 M EDTA, 1% SDS). To obtain the chromatin and soluble fractions, cells were treated with extraction buffer (PBS, 5 mM EDTA, 0.1% Triton X-100) and subjected to pipetting over ten times. The cell lysate was subsequently centrifuged at 1500 g for 5 min to separate the chromatin pellet from the soluble supernatant. The chromatin pellet was then lysed using lysis buffer. After obtaining the whole, chromatin, and soluble fractions, NaCI was added to each fraction (final concentration 1.6 M NaCI). The fractions were then centrifuged at 4°C, 15,000 g for 20 minutes to remove cell debris and obtain the DNA-containing supernatant. To precipitate the DNA, Glycogen (GlycoBlue Coprecipitant, 75  $\mu$ g) was added to the supernatant, followed by the addition of 75% of the supernatant volume of isopropanol.

It has been observed that the isopropanol/ethanol precipitation procedure can result in unreliable nucleotides recovery efficiency, particularly for small nucleic acids when the concentration of nucleic acid is low (9). During isopropanol/ethanol DNA precipitation, the presence of bulk DNA/RNA can act as a carrier, which facilitates the precipitation of small-sized nucleic acids. To overcome this issue, we introduced excessive amounts of glycogen (75  $\mu$ g) as a carrier during the isopropanol precipitation step. Adding glycogen led to a minimum 10% increase in DNA recovery compared to the procedure without glycogen. Additionally, we incubated the mixture at -20 degrees Celsius for a minimum of 3 hours to maximize the precipitation of single-stranded DNA fragments.

The mixture was subjected to additional centrifugation at 4°C, 15,000 g for 20 minutes to obtain the DNA pellet. Subsequently, the DNA pellet was washed twice with 70% ethanol by centrifuging at 15,000 g for 5 minutes each time. Finally, the DNA pellet was dissolved in DW (distilled water) and incubated overnight at 4 °C to ensure complete dissolution. The DNA concentration was measured using Qubit (Qubit dsDNA HS Assay Kit, Invitrogen) or a nanodrop spectrophotometer.

#### - Southern blot procedure

For electrophoresis, 100-400 ng of whole DNA, measured using Qubit, was loaded into 0.6% Agarose gel and run at 40 V (2.9V/cm) in TAE (Tris-acetate EDTA) buffer. Subsequently, the agarose gel underwent sequential incubations in the following solutions: Depurination solution (0.2 M HCl) for 5 minutes, Denaturation solution (0.5 M NaOH, 1.5 M NaCl) for 5 minutes, and Neutralization Buffer (0.5 M Tris pH 8.0, 1.5 M NaCl) for 20 minutes. The DNA was then transferred onto a Nylon membrane (Nylon Membranes, positively charged, Roche) using a Vacuum Blotting System (VacuGene XL) at 30 mbar for 1 hour in 4xSSC (Saline Sodium Citrate) buffer. Following this, the membrane was incubated with 1 nM DIG (Digoxigenin)-labeled Telomere probes in Hybridization solution (DIG Easy Hyb, Roche) at 42°C. Afterward, the membrane underwent two washes with Wash buffer 1 (2xSSC, 0.1% SDS) for 10 minutes each. The membrane was then

blocked with Blocking solution (1% Blocking reagent, Roche 11096176001, in Maleic acid buffer pH 7.4) for 30 minutes, followed by incubation with 0.2% Anti-Digoxigenin-AP Fab fragments (Roche) in Blocking solution for 1 hour. Subsequently, the membrane underwent two washes with Wash buffer 3 (Maleic acid, 0.3% tween-20) for 15 minutes each. Finally, the membrane was incubated with 1% CDP-star (Roche 11759051001) in AP buffer (50 mM Tris pH 9.5, 100 mM NaCl) for detection, which was performed using the Odyssey Imaging System (LI-COR 2800).

### - Strand specific probe generation procedure

For the generation of strand-specific probes, we made minor modifications to the previous protocol (10). Annealed templates (TC, TG, and UP\* in the list below) were generated at a concentration of 40  $\mu$ M in NEBuffer#2.1 (NEB) buffer. The templates were then incubated with 50 units of exo-Klenow enzyme (NEB) and 1 mM dNTP with 0.35 mM DIG-dUTP (biorbyt) at 25°C overnight, followed by heat inactivation at 75°C for 20 minutes. Subsequently, we performed a 10-unit T4 DNA polymerase reaction to improve specificity. The double-stranded oligos were purified using NucleoSpin Gel and PCR clean-up (MN) with NTI buffer following the manufacturer's instructions. Next, a 20-unit lambda exonuclease reaction was carried out to obtain single-stranded oligos for 1 hour at 37°C. Finally, the single-stranded telomere probes were purified using NucleoSpin Gel and PCR clean-up (MN) with NTC buffer. Following oligos were used:

Telomere C-rich probe template (TC):

5'[Phos]GGGTTÅGGGTTÅGGGTTÅGGGTTÅGGGTTÅGGGTTÅGGGTTÅGGGTTÅGAGÅGTC-3' Telomere G-rich probe template (TG):

5'[Phos]CCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAGATAGTTGAGAGAGTC-3' Universal priming oligo (UP\*): 5'-[Phos]GACTCTCAAC\*T\*A\*T\*C\*T\*A-3'

(\*) indicates phosphorothioate bond

### CsCl separation (Cesium gradient analysis)

CsCl separation was performed as previously with minor modification (11). Briefly, cells were treated with 100  $\mu$ M ldU for 20 hours, in conjugation with 10 nM FudR and 100 nM PARG inhibitor to promote ldU-incorporation and the recovery of C-rich ssDNAs. Post-incorporation, genomic DNA was extracted, yielding approximately 200  $\mu$ g using the Puregene Core Kit A from Qiagen. The extracted DNA was then subjected to digestion using a combination of Hinfl and Rsal enzymes. Following digestion, the DNA samples were mixed with a CsCl solution to achieve a target density of 1.770 g/ml. Centrifugation of these samples was performed at a speed of 55,000 rpm for 20 hours, utilizing a VTi-90 vertical rotor from Beckman. After centrifugation, the fractions were collected and a slot blot analysis for each fraction was executed.

#### Cell fractionation using E1 and E2 buffer.

Cells were lysed in E1 buffer (140 mM NaCl, 1 mM EDTA, 50 mM HEPES-KOH pH 7.5, 0.5% NP-40, 10% glycerol, and 0.25% Triton X-100). After mixing, the mixture was centrifuged at 2000 g for 2 minutes. The supernatant was prepared as the cytoplasm fraction. The pellet was then washed twice with E1 buffer, centrifuging at 1000 g for 2 minutes each time. On the second wash, the pellet was incubated on ice for 15 minutes. Subsequently, the pellet was resuspended in E2 buffer (200 mM NaCl, 1 mM EDTA, 10 mM Tris pH 8, and 0.5 mM EGTA pH 8). After a 20-minute incubation on ice, the supernatant was collected (nucleoplasm fraction). The remaining pellet was designated as the chromatin fraction.

#### Nascent C-rich ssDNA pull-down (native IdU-immunoprecipitation)

IdU-pulldown was conducted under native conditions (without heat or denaturation), as detailed described (37). Cells were exposed to 100  $\mu$ M IdU for 20 hours (with Mirin concurrently in Fig.3).

Genomic DNAs from chromatin and soluble fractions were harvested from approximately 10 million cells. 1  $\mu$ g of this genomic DNA from soluble fraction was mixed with 3  $\mu$ g of anti-IdU/BrdU antibody (3D4 clone, BD Science) in BrdU-IP buffer composed of PBS and 0.0625% Triton X-100 overnight. This mixture was then subjected to a 1-hour incubation with Protein G magnetic beads. The immunoprecipitated DNA was subsequently eluted using an elution buffer (10 mM Tris pH 8 and 1% SDS). The elution was performed at room temperature and agitated at 1000 rpm for 1 hour. This was then purified using NucleoSpin Gel and PCR clean-up (MN) with NTC buffer. Eluted samples were analyzed using a native agarose gel electrophoresis.

### C-circle assay

Genomic DNAs were subjected to incubation with 10 units of phi29 polymerase (NxGen phi29), 0.2 mM dNTP mix, and 1X phi29 buffer at 30°C for 12 hours, followed by a 20-minute incubation at 65°C. Subsequently, the samples were loaded onto a Nylon membrane using a slot-blot technique. The subsequent steps of hybridization and detection followed the same procedure as described in the 4SET method.

#### Western Blot

Samples were treated with Laemmli loading buffer (2% SDS, 5% beta-mercaptoethanol, 10% Glycerol, 0.002% Bromophenol Blue, 62.5 mM Tris-base) and subjected to 10 seconds of ultrasonication. The prepared samples were then separated on a Bis-Tris or Tris-HCl polyacrylamide gels and transferred to a PVDF membrane using the iBlot 2 Dry Blotting or Trans-Blot System. After blocking with 5% skim milk or 3% BSA in PBS-T (PBS-0.1% Tween-20) for 1 hour at room temperature, the membrane was incubated with the primary antibody overnight at 4°C. Following PBS-T wash, the membrane was incubated with the secondary antibody for 1 hour at room temperature. After an additional PBS-T wash, the ECL solution was applied, and detection was performed using the Odyssey Imaging System (LI-COR 2800).

#### Antibodies

The following antibodies were used for Western Blot: anti-Beta actin (Sigma-Aldrich, A5316), anti-Histone H3 (Cell signaling, 2650), anti-ATRX (Santa Cruz, sc-15408), anti-hMRE-11 (Calbiochem, PC388), anti-GAPDH (Cell signaling, 97166), anti-Lamin A/C (Santa Cruz, sc-376248), anti-Emerin (Santa Cruz, sc-25284), anti-RAD51AP1 (Proteintech, 11255), anti-DAXX (Santa Cruz, sc-8043), anti-DNA2 (Proteintech, 18727-1-AP), anti-FEN1 (Santa Cruz, sc-28355), anti-PRIMPOL (Proteintech, 29824-1-AP), anti-STN1 (Abcam, ab89250), and anti-POLD3 (Proteintech, 21935-1-AP).

#### **RNA** extraction and quantification

For RNA quantification, total RNA was extracted by using Direct-zol RNA Miniprep kits (ZYMO) according to the manufacturer's protocol. cDNAs were synthesized using RevertAid First Strand cDNA synthesis kit (Thermo scientific) and qPCRs were performed using TB Green Premix Ex Taq II (Tli RNase H Plus) (Takara) according to the manufacturer's protocol.

The following DNA probes were used for qPCR: GAPDH F: TGAGAACGGGAAGCTTGTCA, GAPDH R: AGCATCGCCCCACTTGATT, STN1 F: TGCACAGAAAGATCCACCGG, STN1 R: AGGCCAAGATGTGCAGGAA, DNA2 F: ACTGTGAAAAGCGCCTGGT, DNA2 R: AGATGTGCAGTCTCCCTCCA, FEN1 F: TTCTTCAAGGTGACCGGCTC, FEN1 R: TTAAACTTCCCTGCTGCCCC, FANCM F: AGACCTTTATTGCCGCCGT, FANCM R: TTCGTTGGGGCCATGAAGA

#### **Statistical Analyses**

Statistical analyses for the experiments were conducted using GraphPad Prism 8. The graph displays all individual values. Detailed information regarding the tests and corresponding p-values is provided in the figures and their respective legends.

#### **Extended Discussion**

#### 4SET, an efficient and simple method to detect extrachromosomal single stranded DNAs

We demonstrate an efficient and simple method to detect extrachromosomal telomeric ssDNAs called 4SET (Strand-Specific Southern-blot for Single-stranded Extrachromosomal Telomeres) assay. This technique can be performed within two days by molecular biologists at an intermediate level of expertise, without the need for specialized or expensive laboratory equipment, allowing us to investigate single-stranded extrachromosomal telomeres in a time-efficient and cost-effective manner. Additionally, this assay offers a strand-specific approach, allowing for the discrimination of specific telomere strands during analysis. For example, by employing the 4SET assay, here we proposed the model of underlying mechanisms of generation of single-stranded extrachromosomal telomeres which are derived from strand displacement of lagging strands. Furthermore, the simplicity and efficiency of the 4SET assay make it suitable for implementation in various research settings, such as assessing other repeat sequences of interest.

#### Comparison between 4SET and C-circle Assays and the Contribution of the 4SET Assay

In PML knockout Saos-2 cells, the 4SET assay failed to detect any C-rich ssDNAs (Fig. S1I), whereas the C-circle method identified decreased levels of C-circles (Fig. S1J). This observation raises concerns about the sensitivity of the 4SET assay compared to the C-circle assay, particularly in detecting circular forms of C-rich ssDNAs. Such a discrepancy indicates a differential sensitivity between the two assays in identifying circular forms of C-rich ssDNAs.

However, it is important to note that while the C-circle assay is adept at amplifying and detecting Ccircles, it relies on Phi29-polymerase-mediated rolling circle amplification for 12-18 hrs, which can nonspecifically amplify other DNA replication/recombination intermediates (Fig. 1 in Henson et al. (2017) (12)). This characteristic necessitates a higher threshold for determining ALT activity in cancer cells, often set at a 5-fold difference compared with non-ALT cells (13). In contrast, our 4SET assay exhibits a high specificity, consistently failing to detect C-rich ssDNA signals in non-ALT cells. This specificity brings into question the nature of residual C-circle levels in PML KO cells – whether they are true C-circle signals or artefacts of DNA replication/recombination intermediate amplification (12). Moreover, the unique ability of the 4SET assay to isolate and detect C-rich ssDNAs originating from the daughter strand of lagging strands, as presented in Fig 2, is an advancement. This capability is crucial for hypothesizing that C-rich ssDNAs are derived from the Okazaki fragment processing, providing a foundational understanding that is not attainable with the C-circle assay alone. In essence, while both assays have their merits, the 4SET assay contributes new insights, particularly regarding the origin and formation mechanism of C-rich ssDNAs, thereby complementing and extending the findings obtainable through the C-circle assay, as we demonstrate a new model here.

### **SI References**

- 1. A. Emam *et al.*, Stalled replication fork protection limits cGAS-STING and P-body-dependent innate immune signalling. *Nat Cell Biol* **24**, 1154-1164 (2022).
- 2. I.-C. Cheng *et al.*, Wuho is a new member in maintaining genome stability through its interaction with flap endonuclease 1. *PLoS biology* **14**, e1002349 (2016).
- 3. A. Taglialatela *et al.*, REV1-Polzeta maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. *Mol Cell* **81**, 4008-4025 e4007 (2021).
- 4. X. Pan *et al.*, FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops. *Sci Rep* **9**, 19110 (2019).
- 5. W. Chai, A. J. Sfeir, H. Hoshiyama, J. W. Shay, W. E. Wright, The involvement of the Mre11/Rad50/Nbs1 complex in the generation of G-overhangs at human telomeres. *EMBO Rep* **7**, 225-230 (2006).
- 6. S. Li *et al.*, PIF1 helicase promotes break-induced replication in mammalian cells. *EMBO J* 40, e104509 (2021).
- 7. C. Huang, X. Dai, W. Chai, Human Stn1 protects telomere integrity by promoting efficient lagging-strand synthesis at telomeres and mediating C-strand fill-in. *Cell Res* **22**, 1681-1695 (2012).
- 8. C. A. Lovejoy *et al.*, Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. *PLoS Genet* **8**, e1002772 (2012).
- 9. Y. K. Kim, J. Yeo, B. Kim, M. Ha, V. N. Kim, Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. *Mol Cell* **46**, 893-895 (2012).
- 10. T. P. Lai, W. E. Wright, J. W. Shay, Generation of digoxigenin-incorporated probes to enhance DNA detection sensitivity. *Biotechniques* **60**, 306-309 (2016).
- 11. J. Min, W. E. Wright, J. W. Shay, Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands. *Nucleic Acids Res* **45**, 2615-2628 (2017).
- 12. J. D. Henson *et al.*, The C-Circle Assay for alternative-lengthening-of-telomeres activity. *Methods* **114**, 74-84 (2017).
- 13. Y. Y. Chen *et al.*, The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity. *Cancers (Basel)* **13** (2021).

# Uncropped WB

# Figure S1D



# Figure S1O







# Figure S3E

# Figure S3H







IB : beta-actin

Figure S4A





Figure S4C



IB : beta-actin

IB : beta-actin

# Figure S4G





### **IB : PRIMPOL**

# Figure S4I



**IB : PRIMPOL** 

Figure 5A



250 150 100 75

**IB : ATRX** 



IB : MRE11

Figure S5F



# Figure S6A



IB : STN1

IB : beta-actin